[HTML][HTML] Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple …
HM Bajwa, F Novak, AC Nilsson, C Nielsen… - Multiple sclerosis and …, 2022 - Elsevier
Objective To examine humoral and cellular response in multiple sclerosis patients on anti-
CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A …
CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A …
Memory B cell–guided extended interval dosing of ocrelizumab in multiple sclerosis
D Meng, R Sacco, G Disanto, F Widmer… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background: Ocrelizumab (OCR) is an anti-CD20 monoclonal antibody approved for the
treatment of relapsing-remitting and primary-progressive multiple sclerosis (MS). We aimed …
treatment of relapsing-remitting and primary-progressive multiple sclerosis (MS). We aimed …
Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
M Nasello, V Zancan, V Rinaldi, A Marrone… - International Journal of …, 2024 - mdpi.com
Ocrelizumab (OCR), an anti-CD20 monoclonal antibody, is approved for treating relapsing
remitting (RR) and primary progressive (PP) multiple sclerosis (MS). The standard interval …
remitting (RR) and primary progressive (PP) multiple sclerosis (MS). The standard interval …
New Approaches to Challenge Old Assumptions—B-Cell Depletion in Multiple Sclerosis
L Oommen, S Krieger - JAMA neurology, 2023 - jamanetwork.com
Rituximab is a first-generation chimeric CD20–targeted mAb that has been studied in both
relapsing and progressive forms of MS. Despite promising phase 2 trial data for rituximab in …
relapsing and progressive forms of MS. Despite promising phase 2 trial data for rituximab in …
Modeling Multiple Sclerosis Medication in Mice: Regulatory B Cells Escape Long-Term αCD20 B Cell-Depletion, Preserving Health in the Face of Autoimmunity
SD Neu - 2023 - search.proquest.com
Abstract αCD20 B cell-depleting antibody (αCD20) therapy has become a first-line treatment
for multiple sclerosis (MS), and while the mechanism for this efficacy is incompletely …
for multiple sclerosis (MS), and while the mechanism for this efficacy is incompletely …
[HTML][HTML] Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Patients With MS
MD Kornberg, MA AbdelRazek - practiceupdate.com
Extended-interval dosing of anti-CD20 therapies has been suggested as a strategy to limit
treatment risks while maintaining efficacy. This study evaluated the rate of clinical and …
treatment risks while maintaining efficacy. This study evaluated the rate of clinical and …